

Ad hoc announcement pursuant to Art. 16 LR **Publication of the Annual Financials**

RELEASE – AUDITED CONSOLIDATED & STATUTORY FINANCIAL STATEMENTS

Zug, 11th July 2022

The audited consolidated and statutory financial statements for the full year ended 31st March 2022 were approved by the Board of Directors at their meeting held on July 8th, 2022.

Audited consolidated financial statements for the full year ended 31st March 2022

The presentation currency for the consolidated financial statements is USD.

Audited consolidated income statement

Total Revenue

Consolidated Revenues for the Financial Year 2021-22 were at USD 329.60 million, an increase of 6.7% over the same period in the previous year.

Gross Margin

The Gross Margin was at 61.3% during the Financial Year 2021-22, compared to 62.7% over the same period in the previous year.

Operating Result

The Operating Profit for the Financial Year 2021-22 was at USD 21.93 million, compared to an Operating profit of USD 44.49 over the same period in the previous year. The Research & Development expenses stood at 8.4% of Total Revenue in the Financial Year 2021-22 at USD 27.78 million. Total R&D spend including capex accounted for USD 46.71 million at 14.2% of Total Revenue.

Profit/(Loss)

The Loss for the Financial Year 2021-22 was USD 2.97 million, compared to a profit of USD 37.29 million over the same period in the previous year. The loss for the Financial Year 2021-22 resulted mostly from additional R&D expenses and extraordinary loss.

Audited consolidated balance sheet

Balance sheet as at 31st March 2022

The Net Debt to Equity ratio as at 31st March 2022 stands at 0.07 compared to 0.31 as at 31st March 2021.

On 31st March 2022, Current and Non-current financial liabilities decreased at USD 59.23 million from USD 143.44 million on 31st March 2021.

On 31st March 2022, Cash & cash equivalents and Securities totaled USD 38.50 million compared to USD 53.42 million as on 31st March 2021.

This press release, about the audited consolidated and statutory financial statements for the full year ended 31st March 2022 is also available in electronic form at www.wockhardtbio.com

Stock Listing

The registered shares of Wockhardt Bio AG are traded at the BX Bern eXchange.

Ticker Symbols:

WBIO (Telekurs)
Securities nummer 19304250
ISIN CH 019 304 250 1

Stock Listing

Contact: Mr Ajay Sahni
asahni@wockhardt.com

Phone: +41.41.727.5226